NCT07827729

Brief Summary

Purpose: This study aimed to compare the effects of aromatherapy and music listening with routine care on sleep parameters and cerebral oxygenation in children with epilepsy. Design and methods: This randomized controlled experimental study was conducted between February and December 2023 with children diagnosed with epilepsy living in Malatya Province and surrounding regions. The sample consisted of 90 children allocated to aromatherapy (n = 30), music listening (n = 30), and control (n = 30) groups. Children in the intervention groups received aromatherapy or music listening, whereas the control group received routine care only. Data were collected using the Patient Introduction and Follow-up Form, actigraphy, and the Cerebral Oxygen Monitoring Form. One-way ANOVA, Kruskal-Wallis, chi-square, Mann-Whitney U, LSD, and Dunnett's C tests were used for data analysis. Results: Aromatherapy was associated with higher cerebral oxygen levels, longer time spent in bed, longer sleep duration, higher sleep efficiency, and lower sleep onset latency (p \< 0.05). Similarly, music listening was associated with higher cerebral oxygen levels, longer sleep duration, and higher sleep efficiency (p \< 0.05). Conclusion: Aromatherapy and music listening may improve selected sleep parameters and cerebral oxygenation in children with epilepsy. Practice implications: Aromatherapy and music listening may be considered supportive, non-pharmacological interventions for improving sleep and cerebral oxygenation in pediatric epilepsy care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 28, 2023

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

September 11, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 18, 2026

Completed
Last Updated

September 18, 2026

Status Verified

September 1, 2026

Enrollment Period

7 months

First QC Date

September 11, 2026

Last Update Submit

September 16, 2026

Conditions

Keywords

AromatherapyMusic listeningEpilepsySleepCerebral oxygen

Outcome Measures

Primary Outcomes (7)

  • Time Spent in Bed

    Time spent in bed was objectively assessed using the Actiwatch 2 actigraphy device and Actiware 6 software. It represents the total time the child spent in bed during the monitored sleep period and was expressed in hours.

    24-hour actigraphy monitoring period

  • Awakening Time During Sleep

    Awakening time during sleep was objectively assessed using the Actiwatch 2 actigraphy device and Actiware 6 software. It represents the total duration of wakefulness occurring after sleep onset and before the end of the sleep period and was expressed in

    24-hour actigraphy monitoring period

  • Number of Awakenings During Sleep

    The number of awakenings during sleep was objectively assessed using the Actiwatch 2 actigraphy device and Actiware 6 software. It represents the number of episodes scored as wakefulness occurring during the monitored sleep period and was reported as a count.

    24-hour actigraphy monitoring period

  • Sleep Duration

    Sleep duration was objectively assessed using the Actiwatch 2 actigraphy device and Actiware 6 software. It represents the total amount of time scored as sleep during the monitored sleep period and was expressed in hours.

    24-hour actigraphy monitoring period

  • Sleep Onset Latency

    Sleep onset latency was objectively assessed using the Actiwatch 2 actigraphy device and Actiware 6 software. It represents the time from the beginning of the sleep period to sleep onset and was expressed in minutes.

    24-hour actigraphy monitoring period

  • Sleep Efficiency

    Sleep efficiency was objectively assessed using the Actiwatch 2 actigraphy device and Actiware 6 software. It represents the percentage of time spent asleep relative to the total time spent in bed during the monitored sleep period and was expressed as a percentage (%).

    24-hour actigraphy monitoring period

  • Regional Cerebral Oxygen Saturation (rSO₂)

    Regional cerebral oxygen saturation (rSO₂) was assessed noninvasively using near-infrared spectroscopy (NIRS) with the INVOS 5100C system and compatible INVOS pediatric sensors. rSO₂ values were recorded at 30, 60, 90, 120, and 150 minutes during the monitoring period. The five measurements were averaged to obtain one mean rSO₂ value for each participant. Regional cerebral oxygen saturation was expressed as a percentage (%).

    150-minute NIRS monitoring period

Study Arms (3)

Aromatherapy Group

EXPERIMENTAL

Before evening sleep, lavender aromatherapy was administered by inhalation for 30 minutes using a scented pillow. NIRS monitoring was initiated concurrently with the 30-minute aromatherapy intervention and continued for a total of 150 minutes.

Other: Aromatherapy

Music Listening Group

EXPERIMENTAL

Before evening sleep, music selected by the child or parent was played at 45-65 dB for 30 minutes. NIRS monitoring was initiated concurrently with the 30-minute music-listening intervention and continued for a total of 150 minutes.

Other: Music Listening

Control Group

NO INTERVENTION

Routine care only

Interventions

Lavender aromatherapy administered by inhalation using a scented pillow

Aromatherapy Group

Child- or parentselected calming music at 45-65 dB

Music Listening Group

Eligibility Criteria

Age3 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Generalized tonic-clonic seizure,
  • Children who take at least one antiepileptic drug.

You may not qualify if:

  • Children with hearing problems,
  • Children with resistant epilepsy,
  • Children diagnosed with sleep disorders,
  • Children diagnosed with neurological, psychiatric, or medical disorders other than epilepsy,
  • Children with allergies,
  • Children with impaired sense of smell,
  • Children whose parents did not give consent were excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

İnönü University Turgut Özal Medical Center

Malatya, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Epilepsy

Interventions

Aromatherapy

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Mind-Body TherapiesComplementary TherapiesTherapeuticsPhytotherapySensory Art TherapiesPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Emriye Hilal Yayan, Prof. Dr.

    Department of Child Health Nursing Faculty of Nursing, Inonu University, 44280 Malatya, Türkiye

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD Student

Study Record Dates

First Submitted

September 11, 2026

First Posted

September 18, 2026

Study Start

February 1, 2023

Primary Completion

August 15, 2023

Study Completion

December 28, 2023

Last Updated

September 18, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations